Related Experiment Videos
Visual Field Variability after Gene Therapy for Leber's Hereditary Optic Neuropathy
Jia-Jia Yuan1,2, Yong Zhang2, Li-Ling Wang2
1Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ophthalmic Research
|April 13, 2018
Summary
Gene therapy for Leber's hereditary optic neuropathy (LHON) significantly improved visual fields (VF). This treatment, using AAV2-ND4, showed effectiveness even in patients with long-standing disease, benefiting both eyes.
Area of Science:
- Ophthalmology
- Genetics
- Neurology
Background:
- Leber's hereditary optic neuropathy (LHON) is a genetic condition causing vision loss.
- Gene therapy offers a potential treatment avenue for LHON.
Purpose of the Study:
- To evaluate visual field (VF) changes following gene therapy in LHON patients.
- To determine the efficacy of AAV2-ND4 gene therapy for LHON.
Main Methods:
- Nine LHON patients received monocular intravitreal AAV2-ND4 injections.
- Visual fields were compared before and after treatment in injected and uninjected eyes.
- Patients were grouped by disease duration (≤2 years and >2 years).
Main Results:
- A statistically significant improvement in visual fields was observed post-gene therapy.
- No significant difference in VF improvement was noted between injected and uninjected eyes.
- Disease duration did not significantly impact VF improvement outcomes.
Conclusions:
- AAV2-ND4 gene therapy can lead to significant visual field recovery in LHON patients.
- The treatment demonstrates potential for improving binocular vision.
- Gene therapy may be effective even for patients with disease duration exceeding two years.